Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

For Sale: Knight Therapeutics Seeks Buyers For Impavido Priority Review Voucher

This article was originally published in The Pink Sheet Daily

Executive Summary

But the small Canadian specialty company says it will be patient in finding the maximum value for the asset, awarded in connection with FDA approval of its leishmaniasis treatment.

You may also be interested in...



Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less

Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.

Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain

Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.

PCSK9 Meets PRV: Regeneron’s $70 Mil. Bid To Catch Up To Amgen

Regeneron and its partner Sanofi have become the first biopharma companies to buy a Priority Review Voucher. The $67 million price is a nice bonus for the seller, BioMarin, but probably not the start of a big new market for PRVs.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS076982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel